A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19

Favipiravir is an oral broad-spectrum inhibitor of viral RNA-dependent RNA polymerase that is approved for treatment of influenza in Japan. We conducted a prospective, randomized, open-label, multicenter trial of favipiravir for the treatment of COVID-19 at 25 hospitals across Japan. Eligible patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Doi, Yohei, Hibino, Masaya, Hase, Ryota, Yamamoto, Michiko, Kasamatsu, Yu, Hirose, Masahiro, Mutoh, Yoshikazu, Homma, Yoshito, Terada, Masaki, Ogawa, Taku, Kashizaki, Fumihiro, Yokoyama, Toshihiko, Koba, Hayato, Kasahara, Hideki, Yokota, Kazuhisa, Kato, Hideaki, Yoshida, Junichi, Kita, Toshiyuki, Kato, Yasuyuki, Kamio, Tadashi, Kodama, Nobuhiro, Uchida, Yujiro, Ikeda, Nobuhiro, Shinoda, Masahiro, Nakagawa, Atsushi, Nakatsumi, Hiroki, Horiguchi, Tomoya, Iwata, Mitsunaga, Matsuyama, Akifumi, Banno, Sumi, Koseki, Takenao, Teramachi, Mayumi, Miyata, Masami, Tajima, Shigeru, Maeki, Takahiro, Nakayama, Eri, Taniguchi, Satoshi, Lim, Chang Kweng, Saijo, Masayuki, Imai, Takumi, Yoshida, Hisako, Kabata, Daijiro, Shintani, Ayumi, Yuzawa, Yukio, Kondo, Masashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2020
Materias:
Antiviral Agents
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7674035/
https://www.ncbi.nlm.nih.gov/pubmed/32958718
http://dx.doi.org/10.1128/AAC.01897-20

Ejemplares similares

Ejemplares similares